(1) Sculier JP, Paesmans M, Bureau G, Dabouis G, Libert P, Vandermoten G et al. Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party. J Clin Oncol 1993; 11(10):1858-1865.
(2) Souhami RL, Rudd R, Ruiz dEM, James L, Gower N, Harper PG et al. Randomized trial comparing weekly versus 3-week chemotherapy in small- cell lung cancer: a Cancer Research Campaign trial. J Clin Oncol 1994; 12(9):1806-1813.
(3) James LE, Gower NH, Rudd RM, Spiro SG, Harper PG, Trask CW et al. A randomised trial of low-dose/high-frequency chemotherapy as palliative treatment of poor-prognosis small-cell lung cancer: a Cancer research Campaign trial. Br J Cancer 1996; 73(12):1563-1568.
(4) Furuse K, Fukuoka M, Nishiwaki Y, Kurita Y, Watanabe K, Noda K et al. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group. J Clin Oncol 1998; 16(6):2126-2132.
(5) Murray N, Livingston RB, Shepherd FA, James K, Zee B, Langleben A et al. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 1999; 17(8):2300-2308.
(6) Sekine I, Nishiwaki Y, Noda K, Kudoh S, Fukuoka M, Mori K et al. Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI). Ann Oncol 2003; 14(5):709-714.